Last reviewed · How we verify

NYPOZI — Competitive Intelligence Brief

NYPOZI (FILGRASTIM-TXID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Leukocyte Growth Factor [EPC]. Area: Other.

marketed Leukocyte Growth Factor [EPC] Specific cell surface receptors on hematopoietic cells Other Live · refreshed every 30 min

Target snapshot

NYPOZI (FILGRASTIM-TXID) — TANVEX BIOPHARMA USA INC. G-CSF binds to specific receptors on hematopoietic cells, stimulating neutrophil production and function.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NYPOZI TARGET FILGRASTIM-TXID TANVEX BIOPHARMA USA INC marketed Leukocyte Growth Factor [EPC] Specific cell surface receptors on hematopoietic cells
FILGRASTIM FILGRASTIM marketed Leukocyte Growth Factor [EPC] Specific cell surface receptors on hematopoietic cells 1991-01-01
Rolvedon EFLAPEGRASTIM Spectrum Pharms marketed Leukocyte Growth Factor [EPC] Granulocyte colony-stimulating factor receptor 2022-01-01
Neulasta PEGFILGRASTIM Amgen marketed Leukocyte Growth Factor [EPC] Granulocyte colony-stimulating factor receptor 2002-01-01
Neupogen Filgrastim-Aafi Amgen marketed Colony-stimulating factor (CSF); leukocyte growth factor G-CSF receptor (granulocyte colony-stimulating factor receptor) 1991-01-01
Leukine SARGRAMOSTIM Berlex Labs marketed Leukocyte Growth Factor [EPC] Granulocyte macrophage colony-stimulating factor receptor 1991-01-01
ROLVEDON EFLAPEGRASTIM-XNST SPECTRUM PHARMS marketed Leukocyte Growth Factor [EPC] Granulocyte colony-stimulating factor receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Leukocyte Growth Factor [EPC] class)

  1. KASHIV BIOSCIENCES LLC · 2 drugs in this class
  2. Amgen · 1 drug in this class
  3. Berlex Labs · 1 drug in this class
  4. EVIVE BIOTECHNOLOGY · 1 drug in this class
  5. FRESENIUS KABI USA · 1 drug in this class
  6. LUPIN LTD · 1 drug in this class
  7. MYLAN GMBH · 1 drug in this class
  8. SANDOZ INC · 1 drug in this class
  9. SPECTRUM PHARMS · 1 drug in this class
  10. Spectrum Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NYPOZI — Competitive Intelligence Brief. https://druglandscape.com/ci/filgrastim-txid. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing